IM-1021
ROR1-positive Tumors (Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Mantle-Cell Lymphoma)
Phase 1Enrollment initiated in Q1 2025
Key Facts
Indication
ROR1-positive Tumors (Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Mantle-Cell Lymphoma)
Phase
Phase 1
Status
Enrollment initiated in Q1 2025
Company
About Immunome
Immunome is a clinical-stage biotech dedicated to improving outcomes for cancer patients through a portfolio of targeted therapies, primarily centered on antibody-drug conjugates (ADCs). The company's most advanced asset is varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors, complemented by earlier-stage ADC and radioligand programs. Under the leadership of CEO Clay Siegall, co-founder of Seagen, Immunome leverages significant ADC expertise to pursue differentiated targets and optimize therapeutic candidates for efficacy and tolerability.
View full company profile